Literature DB >> 12940904

Dose determinants in continuous renal replacement therapy.

William R Clark1, Joseph E Turk, Michael A Kraus, Dayong Gao.   

Abstract

Increasing attention is being paid to quantifying the dose of dialysis prescribed and delivered to critically ill patients with acute renal failure (ARF). Recent trials in both the intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT) realms have suggested that a direct relationship between dose and survival exists for both of these therapies. The purpose of this review, first, is to analyze critically the above-mentioned dose/outcome studies in acute dialysis. Subsequently, the factors influencing dose prescription and delivery are discussed, with the focus on continuous venovenous hemofiltration (CVVH). Specifically, differences between postdilution and predilution CVVH will be highlighted, and the importance of blood flow rate in dose delivery for these therapies will be discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12940904     DOI: 10.1046/j.1525-1594.2003.07288.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  10 in total

Review 1.  Effluent volume and dialysis dose in CRRT: time for reappraisal.

Authors:  Etienne Macedo; Rolando Claure-Del Granado; Ravindra L Mehta
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

Review 2.  The dark side of high-intensity renal replacement therapy of acute kidney injury in critically ill patients.

Authors:  Helmut Schiffl
Journal:  Int Urol Nephrol       Date:  2010-04-10       Impact factor: 2.370

Review 3.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

4.  Solute clearance in CRRT: prescribed dose versus actual delivered dose.

Authors:  William D Lyndon; Keith M Wille; Ashita J Tolwani
Journal:  Nephrol Dial Transplant       Date:  2011-09-05       Impact factor: 5.992

Review 5.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

6.  Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis.

Authors:  Rolando Claure-Del Granado; Etienne Macedo; Glenn M Chertow; Sharon Soroko; Jonathan Himmelfarb; T Alp Ikizler; Emil P Paganini; Ravindra L Mehta
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 8.237

Review 7.  Dose of Continuous Renal Replacement Therapy in Critically Ill Patients: A Bona Fide Quality Indicator.

Authors:  Enzo Vásquez Jiménez; Samaya J Anumudu; Javier A Neyra
Journal:  Nephron       Date:  2021-02-04       Impact factor: 2.847

Review 8.  Nomenclature for renal replacement therapy in acute kidney injury: basic principles.

Authors:  Mauro Neri; Gianluca Villa; Francesco Garzotto; Sean Bagshaw; Rinaldo Bellomo; Jorge Cerda; Fiorenza Ferrari; Silvia Guggia; Michael Joannidis; John Kellum; Jeong Chul Kim; Ravindra L Mehta; Zaccaria Ricci; Alberto Trevisani; Silvio Marafon; William R Clark; Jean-Louis Vincent; Claudio Ronco
Journal:  Crit Care       Date:  2016-10-10       Impact factor: 9.097

9.  Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study.

Authors:  Suvi T Vaara; Anna-Maija Korhonen; Kirsi-Maija Kaukonen; Sara Nisula; Outi Inkinen; Sanna Hoppu; Jouko J Laurila; Leena Mildh; Matti Reinikainen; Vesa Lund; Ilkka Parviainen; Ville Pettilä
Journal:  Crit Care       Date:  2012-10-17       Impact factor: 9.097

10.  Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy.

Authors:  Xiaoying Xu; Dmytro Khadzhynov; Harm Peters; Ricardo L Chaves; Kamal Hamed; Micha Levi; Natascia Corti
Journal:  Br J Clin Pharmacol       Date:  2016-10-28       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.